TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06403852

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI) with propofol
Description: Three 16-min sessions in wakeful baseline, light sedation, and recovery will be conducted (Fig. 2). Light sedation will be achieved by IV infusion of propofol to achieve effect-site concentrations of 1.0 μg/ml. Infusion rate will be manually controlled. An initial bolus dose (525 µg/kg) and subsequent infusion rate (82 µg/kg/min) for each participant
Study: NCT05118243

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control cracker
Description: The gut symptoms caused by control crackers are studied in IBS persons

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme-treated cracker
Description: The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
Study: NCT05340374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.
Study: NCT06303921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-M503 PET
Description: 2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: MRI scan of brain.
Study: NCT05975294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amixture 0.125% bupivicaine with fentanyl
Description: ultrasound guided continuous erector spinae plane block with abolus 0.3ml /kg of amixture 0.125% bupivicaine with fentanyl of 2 mic per ml then Infusion of 0.1 ml /kg/hr of the same mixture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset
Description: PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
Study: NCT05886335

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Time of administration

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Time of administration
Study: NCT04884399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB818
Description: vascular endothelial growth factor (VEGF) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis®
Description: vascular endothelial growth factor (VEGF) inhibitor
Study: NCT05822609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: 1.0 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05165030

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: clinical-radiological evaluation, genetic analysis by whole exome sequencing and constitution of a bio-collection
Study: NCT06018194

Intervention type: DEVICE
Intervention: ElucidVivo
Description: Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
Study: NCT06046326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual community of practice
Description: The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
Study: NCT04211766

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Given fiber supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Given fiber supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Given fish oil supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Given fish oil supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Given fiber supplement placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Given fiber supplement placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Given fish oil supplement placebo (corn oil)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Given fish oil supplement placebo (corn oil)
Study: NCT06185751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WS-CART-CS1
Description: -Subject will be hospitalized for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting chemotherapy
Description: * Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting chemotherapy
Description: * Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3
Study: NCT06571617

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini PCNL (mini percutaneous nephrolithotomy)
Description: half of the cases will be treated using mini PCNL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS (retrograde intrarenal surgery/ flexible URS)
Description: THE OTHER HALF WILL BE TRAETED USING Flexible URS
Study: NCT06569732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homemade oral nutrition supplements
Description: The homemade oral nutrition supplement is made of soy milk, whey protein powder, vegetable oil, and fruit juices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercial oral nutrition supplements
Description: The commercial oral nutrition supplement is kidney-specific oral nutrition supplement that is high in energy and protein, but low in electrolytes and fluid
Study: NCT06303921

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amyloid PET
Description: PET scan with Florbetaben F18 or 11C-PiB

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurological assessments
Description: Neurological assessments, including a video interview.
Study: NCT06157151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-2009 plus Pembrolizumab
Description: Subjects randomized will receive PRGN-2009 (5 x 10\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab alone
Description: Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.
Study: NCT05208697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Harm Reduction
Description: THR is telehealth-enhanced, on-demand services including low-barrier access to antiretrovirals, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an SSP, integrated with the provision of evidence-based naloxone and injection equipment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: off-site linkage
Description: standard of care linkage to a Ryan White clinic
Study: NCT04971707

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized exercise training
Description: HRV index will be measured every morning during 5 min. This group will benefit from the standard cardiovascular rehabilitation program combining both continuous moderate exercise sessions (MICT) and high intensity interval exercise sessions (HIIT). MICT sessions will be performed 2 times per week and HIIT sessions will be performed once a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV-guided exercise training
Description: HRV index will be measured every morning during 5 min. This group will benefit from the individualized cardiovascular rehabilitation program. Daily exercise (MICT, HIIT, or active recovery) will be prescribed according to the HRV-index measured on the morning of the session.
Study: NCT04134052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine sedation versus midazolam sedation
Description: Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine sedation versus midazolam sedation
Description: Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
Study: NCT05419557

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Family-Based Healthy Plate Club
Description: IHPC provides produce boxes, nutrition and meal-preparation, education, and supportive counseling to address barriers related to obtaining produce and food. The intervention provides participants with a bi-weekly produce box for 12 weeks and helps families identify sustainable ways to obtain vegetables once the produce boxes end. The CHW will support families by coaching them on how to prepare these unfamiliar vegetables, give tips on finding sales at grocery stores, as well as by navigation to food assistance sites including food pantries. Parents will learn strategies to increase vegetable consumption by addressing perceived barriers - such as the child doesn't like vegetables. Curriculum will also include topics such as how to increase physical activity and reduce screen time.
Study: NCT05765734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS3351 oral administration
Description: TAS3351 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS3351 oral administration
Description: TAS3351 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS3351 oral administration
Description: TAS3351 will be administered orally
Study: NCT06481839

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Starting dose of NE
Description: Patients will be randomized to either low-dose (5mcg/min) or high-dose (15mcg/min) norepinephrine (NE) for their first vasopressor in shock.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Starting dose of NE
Description: Patients will be randomized to either low-dose (5mcg/min) or high-dose (15mcg/min) norepinephrine (NE) for their first vasopressor in shock.
Study: NCT05439655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Interchange System
Description: The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
Study: NCT05192733

Intervention type: OTHER
Intervention: Survey
Description: This is a cross-sectional practice survey. There is no intervention.

Intervention type: OTHER
Intervention: Survey
Description: This is a cross-sectional practice survey. There is no intervention.
Study: NCT04727931

Intervention type: BEHAVIORAL
Intervention: Neuropsychological assessement and questionnaires
Description: Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.

Intervention type: BEHAVIORAL
Intervention: Neuropsychological assessement and questionnaires
Description: Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
Study: NCT05352178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy (SBRT) and/or surgery (metastasectomy)
Description: Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy (SBRT) and/or surgery (metastasectomy)
Description: Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy (SBRT) and/or surgery (metastasectomy)
Description: Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen receptor targeted therapy
Description: Enzalutamide
Study: NCT06203236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide 20 MG
Description: 1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide 20 MG
Description: 1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diuretic therapy
Description: diuretic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diuretic therapy
Description: diuretic therapy
Study: NCT06293131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
Study: NCT05055128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842
Description: Patients will receive X842 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842
Description: Patients will receive X842 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842
Description: Patients will receive X842 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842
Description: Patients will receive X842 tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: X842 Dummy
Description: Patients will receive matching placebo tablets for X842.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842 Dummy
Description: Patients will receive matching placebo tablets for X842.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842 Dummy
Description: Patients will receive matching placebo tablets for X842.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Patients will receive Lansoprazole capsule.
Study: NCT04962334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation standardized formula.
Description: Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low caloric formula (powder added to water) without added vitamins and minerals
Study: NCT06392360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine
Description: White betaine powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White placebo powder
Study: NCT05676528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
Study: NCT05723055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
Study: NCT05313633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Both groups received a designed occupational therapy program for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Both groups received a designed occupational therapy program for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: The designed plyometric training program basically focuses on upper extremity strength training and is developed according to the guidelines of the National Strength and Conditioning Association.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii training
Description: The dose of Wii training was 40 minutes, three times a week for 12 weeks which is an interactive motion-based device.
Study: NCT05520996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyberball
Description: Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence
Study: NCT05528042

Intervention type: OTHER
Group type: OTHER
Intervention: Heart rate and respiratory rate measurement
Description: Validation of the performance of the heart rate (HR) measurement using COBOX medical device compared to a measurement carried out by applying the reference processes for taking measurements via a CE marked device.~Evaluation of the performance of the respiratory rate (RR) measurement using COBOX medical device compared to a measurement carried out by a reference method of manual counting
Study: NCT06306612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Chemohormonal Therapy
Description: Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Chemohormonal Therapy
Description: Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Hormonal Therapy
Description: Under continuous ADT, oral darolutamide 600mg twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Hormonal Therapy
Description: Under continuous ADT, oral darolutamide 600mg twice per day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Prostatectomy
Description: Cytoreductive prostatectomy was performed after six cycles of neoadjuvant systemic chemohormonal therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative Adjuvant Radiotherapy
Description: Postoperative adjuvant radiotherapy of prostate bed is performed, if margin positive, with conventional segmentation and the dose of 64-72Gy.
Study: NCT05070403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 40 MG
Description: Participants will receive 40 mg Afatinib, once daily.